Duska LR, Petroni GR, Varhegyi N, Brown J, et al. A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol 2020;157:585-592.
PMID: 32247603